hiv envelope protein gp41

Summary

Summary: Transmembrane envelope protein of the HUMAN IMMUNODEFICIENCY VIRUS which is encoded by the HIV env gene. It has a molecular weight of 41,000 and is glycosylated. The N-terminal part of gp41 is thought to be involved in CELL FUSION with the CD4 ANTIGENS of T4 LYMPHOCYTES, leading to syncytial formation. Gp41 is one of the most common HIV antigens detected by IMMUNOBLOTTING.

Top Publications

  1. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
  2. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
  3. pmc Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    Xiping Wei
    Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
    Antimicrob Agents Chemother 46:1896-905. 2002
  4. doi Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
    Nature 458:636-40. 2009
  5. pmc Elicitation of structure-specific antibodies by epitope scaffolds
    Gilad Ofek
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:17880-7. 2010
  6. pmc Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
    Yuxing Li
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892 3005, USA
    J Virol 83:1045-59. 2009
  7. pmc Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility
    Marie Pancera
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:1166-71. 2010
  8. doi Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
    Jinghe Huang
    HIV Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 491:406-12. 2012
  9. ncbi Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Barton F Haynes
    Duke University School of Medicine, Durham, NC 27710, USA
    Science 308:1906-8. 2005
  10. pmc Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer
    Youdong Mao
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA
    Nat Struct Mol Biol 19:893-9. 2012

Detail Information

Publications226 found, 100 shown here

  1. pmc Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, Scripps Research Institute, La Jolla, CA 92037, USA
    Science 326:285-9. 2009
    ..The results provide a framework for the design of new vaccine candidates for the elicitation of bNAb responses...
  2. ncbi Antibody neutralization and escape by HIV-1
    Xiping Wei
    Howard Hughes Medical Institute, University of Alabama at Birmingham, 720 South 20th Street, Kaul 816, Birmingham, Alabama 35294 0024, USA
    Nature 422:307-12. 2003
    ..The evolving glycan shield thus represents a new mechanism contributing to HIV-1 persistence in the face of an evolving antibody repertoire...
  3. pmc Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy
    Xiping Wei
    Howard Hughes Medical Institute, Department of Medicine, University of Alabama at Birmingham, 35294, USA
    Antimicrob Agents Chemother 46:1896-905. 2002
    ..These findings provide the first evidence for the rapid emergence of clinical resistance to a novel class of HIV-1 entry inhibitors and may be relevant to future treatment strategies involving these agents...
  4. doi Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals
    Johannes F Scheid
    Laboratory of Molecular Immunology, The Rockefeller University, New York, New York 10065, USA
    Nature 458:636-40. 2009
    ..Thus, the IgG memory B-cell compartment in the selected group of patients with broad serum neutralizing activity to HIV is comprised of multiple clonal responses with neutralizing activity directed against several epitopes on gp120...
  5. pmc Elicitation of structure-specific antibodies by epitope scaffolds
    Gilad Ofek
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:17880-7. 2010
    ..Epitope scaffolds thus provide a means to elicit antibodies that recognize a predetermined target shape and sequence, even if that shape is transient in nature, and a means by which to dissect factors influencing such elicitation...
  6. pmc Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals
    Yuxing Li
    Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892 3005, USA
    J Virol 83:1045-59. 2009
    ..These data allow a more detailed understanding of the humoral responses to the HIV-1 Env protein and provide insights regarding the most relevant targets for HIV-1 vaccine design...
  7. pmc Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility
    Marie Pancera
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA
    Proc Natl Acad Sci U S A 107:1166-71. 2010
    ..A "layered" gp120 architecture thus allows movement among alternative glycoprotein conformations required for virus entry and immune evasion, whereas a beta-sandwich clamp maintains gp120-gp41 interaction and regulates gp41 transitions...
  8. doi Broad and potent neutralization of HIV-1 by a gp41-specific human antibody
    Jinghe Huang
    HIV Specific Immunity Section, Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892, USA
    Nature 491:406-12. 2012
    ..The highly conserved MPER is a target of potent, non-self-reactive neutralizing antibodies, suggesting that HIV-1 vaccines should aim to induce antibodies to this region of HIV-1 envelope glycoprotein...
  9. ncbi Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies
    Barton F Haynes
    Duke University School of Medicine, Durham, NC 27710, USA
    Science 308:1906-8. 2005
    ..These results may have important implications for generating effective neutralizing antibody responses by using HIV-1 vaccines...
  10. pmc Subunit organization of the membrane-bound HIV-1 envelope glycoprotein trimer
    Youdong Mao
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Microbiology and Immunobiology, Harvard Medical School, Boston, Massachusetts, USA
    Nat Struct Mol Biol 19:893-9. 2012
    ..The cage-like architecture, which is unique among characterized viral envelope proteins, restricts antibody access, reflecting requirements imposed by HIV-1 persistence in the host...
  11. pmc A mutation in the human immunodeficiency virus type 1 Gag protein destabilizes the interaction of the envelope protein subunits gp120 and gp41
    Melody R Davis
    Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, TN 37232 2363, USA
    J Virol 80:2405-17. 2006
    ..Our results suggest that an altered interaction between the MA domain of Gag and the gp41 cytoplasmic tail leads to dissociation of gp120 from gp41 during HIV-1 particle assembly, thus resulting in impaired fusion and infectivity...
  12. pmc HIV enters cells via endocytosis and dynamin-dependent fusion with endosomes
    Kosuke Miyauchi
    Institute of Human Virology and Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD 21201, USA
    Cell 137:433-44. 2009
    ..These findings imply that HIV-1 infects cells via endocytosis and envelope glycoprotein- and dynamin-dependent fusion with intracellular compartments...
  13. pmc Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L
    Ann J Hessell
    Department of Immunology and Microbial Science and the International AIDS Vaccine Initiative Neutralizing Antibody Center, The Scripps Research Institute, 10550 N Torrey Pines Road, La Jolla, CA 92037, USA
    J Virol 84:1302-13. 2010
    ..The study confirms the protective potential of 2F5 and 4E10 and supports emphasis on HIV immunogen design based on the MPER region of gp41...
  14. pmc Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope
    Gilad Ofek
    Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Instiutes of Health, Bethesda, MD 20892, USA
    J Virol 78:10724-37. 2004
    ..Based on these structural and biochemical results, immunization strategies for eliciting 2F5- and 4E10-like broadly neutralizing anti-HIV-1 antibodies are proposed...
  15. doi Entry inhibitors in the treatment of HIV-1 infection
    John C Tilton
    Department of Microbiology, University of Pennsylvania, 301C Johnson Pavilion, 3610 Hamilton Walk, Philadelphia, PA 19104, United States
    Antiviral Res 85:91-100. 2010
    ..This article forms part of a special issue of Antiviral Research marking the 25th anniversary of antiretroviral drug discovery and development, Vol 85, issue 1, 2010...
  16. pmc MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1
    Claudia R Ruprecht
    Institute of Medical Virology, University Hospital Zurich, Switzerland
    J Exp Med 208:439-54. 2011
    ....
  17. pmc Enhanced HIV-1 neutralization by antibody heteroligation
    Hugo Mouquet
    Laboratory of Molecular Immunology, The Rockefeller University, New York, NY 10065, USA
    Proc Natl Acad Sci U S A 109:875-80. 2012
    ..Heterotypic bivalent binding enhanced neutralization compared with the parental antibodies. We conclude that antibody recognition and viral neutralization of HIV can be improved by heteroligation...
  18. pmc Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions
    Victor Buzon
    Unit of Virus Host Cell Interactions UMI 3265, Université Joseph Fourier EMBL CNRS, Grenoble, France
    PLoS Pathog 6:e1000880. 2010
    ....
  19. pmc Isolation of a human anti-HIV gp41 membrane proximal region neutralizing antibody by antigen-specific single B cell sorting
    Lynn Morris
    Duke Human Vaccine Institute and Departments of Medicine, Surgery and Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS ONE 6:e23532. 2011
    ..These data indicate that there are multiple immunogenic targets in the C-terminus of the MPER of HIV-1 gp41 envelope and suggests that gp41 neutralizing epitopes may interact with a restricted set of naive B cells during HIV-1 infection...
  20. pmc Antibody mechanics on a membrane-bound HIV segment essential for GP41-targeted viral neutralization
    Mikyung Kim
    Laboratory of Immunobiology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Nat Struct Mol Biol 18:1235-43. 2011
    ..Hence, target neutralization through this lipid-embedded viral segment places stringent requirements on the plasticity of the antibody combining site...
  21. pmc Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions
    Andres Finzi
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Department of Pathology, Division of AIDS, Harvard Medical School, Boston, MA 02115, USA
    Mol Cell 37:656-67. 2010
    ..Thus, despite lack of contact with CD4, the gp120 inner-domain layers govern CD4 triggering by participating in conformational transitions within gp120 and regulating the interaction with gp41...
  22. pmc Soluble CD4 and CD4-mimetic compounds inhibit HIV-1 infection by induction of a short-lived activated state
    Hillel Haim
    Department of Cancer Immunology and AIDS, Dana Farber Cancer Institute, Division of AIDS, Harvard Medical School, Boston, MA, USA
    PLoS Pathog 5:e1000360. 2009
    ..This novel strategy for inhibition may be generally applicable to high-potential-energy viral entry machines that are normally activated by receptor binding...
  23. pmc Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding
    Q J Sattentau
    Academic Department of Genito Urinary Medicine, University College and Middlesex School of Medicine, London, United Kingdom
    J Exp Med 174:407-15. 1991
    ..We propose that these events occurring after CD4 binding are integral components of the membrane fusion reaction between HIV or HIV-infected cells and CD4+ cells...
  24. pmc N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion
    Shibo Jiang
    Lindsley F Kimball Research Institute, New York Blood Center, 310 E 67th St, New York, NY 10021, USA
    Antimicrob Agents Chemother 48:4349-59. 2004
    ..Therefore, NB-2 and NB-64 can be used as lead compounds toward designing and developing more potent small molecule HIV-1 fusion inhibitors targeting gp41...
  25. pmc Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus
    John J Dwyer
    Trimeris Inc, 3500 Paramount Parkway, Morrisville, NC 27560, USA
    Proc Natl Acad Sci U S A 104:12772-7. 2007
    ..The potent antiviral activity against resistant viruses, the difficulty in generating resistant virus, and the extended half-life in vivo make this class of fusion inhibitor peptide attractive for further development...
  26. pmc Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies
    James M Binley
    IMM2, Department of Immunology, The Scripps Research Institute, 10550 N Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 78:13232-52. 2004
    ..As well as the significance for vaccine design, our data have implications for passive-immunization studies in countries where clade C viruses are common, given that only MAbs b12 and 4E10 were effective against viruses from this clade...
  27. ncbi HIV vaccine design and the neutralizing antibody problem
    Dennis R Burton
    Departments of Immunology and Molecular Biology, Scripps Research Institute, La Jolla, California, USA
    Nat Immunol 5:233-6. 2004
  28. pmc Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41
    S Moses Dennison
    Human Vaccine Institute, Duke University School of Medicine, Durham, North Carolina, United States of America
    PLoS ONE 6:e27824. 2011
    ..Nonetheless, the Env-liposome prime-boost immunization strategy induced antibodies that recognized a gp41 fusion intermediate protein and was successful in focusing the antibody response to the desired epitope...
  29. ncbi Dissociation of gp120 from HIV-1 virions induced by soluble CD4
    J P Moore
    Chester Beatty Laboratories, Institute of Cancer Research, London, United Kingdom
    Science 250:1139-42. 1990
    ..This may represent the initial stage in virus-cell and cell-cell fusion. Shedding of gp120 from virions induced by sCD4 may also contribute to the mechanism by which these soluble receptor molecules neutralize HIV-1...
  30. pmc Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions
    Erin M Scherer
    Department of Immunology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 107:1529-34. 2010
    ....
  31. pmc Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions
    S Moses Dennison
    Human Vaccine Institute, Department of Medicine, Duke University School of Medicine, Durham, North Carolina 27710, USA
    J Virol 83:10211-23. 2009
    ..These data have important implications for the design and use of peptide-liposome conjugates as immunogens for the induction of MPER-neutralizing antibodies...
  32. doi HIV-1 broadly neutralizing antibody extracts its epitope from a kinked gp41 ectodomain region on the viral membrane
    Zhen Yu J Sun
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, Boston, MA 02115, USA
    Immunity 28:52-63. 2008
    ....
  33. ncbi HIV-1 gp41 fusogenic function triggers autophagy in uninfected cells
    Melanie Denizot
    CPBS, UM1, UM2, CNRS, Institut de Biologie, Montpellier, France
    Autophagy 4:998-1008. 2008
    ....
  34. pmc Relationship between antibody 2F5 neutralization of HIV-1 and hydrophobicity of its heavy chain third complementarity-determining region
    Gilad Ofek
    Vaccine Research Center, NIAID, National Institutes of Health, Bethesda, Maryland 20892, USA
    J Virol 84:2955-62. 2010
    ..Together, the results provide a more complete understanding of the 2F5 mechanism of HIV-1 neutralization and indicate ways to enhance the potency of MPER-directed antibodies...
  35. ncbi Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody
    P D Kwong
    Department of Biochemistry and Molecular Biophysics, Columbia University, New York, New York 10032, USA
    Nature 393:648-59. 1998
    ..Our results provide a framework for understanding the complex biology of HIV entry into cells and should guide efforts to intervene...
  36. pmc Tail-interacting protein TIP47 is a connector between Gag and Env and is required for Env incorporation into HIV-1 virions
    Sandra Lopez-Verges
    Institut Cochin, Département Maladies Infectieuses, 27 rue du Faubourg Saint Jacques, F 75014 Paris, France
    Proc Natl Acad Sci U S A 103:14947-52. 2006
    ....
  37. pmc The membrane-proximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design
    Marinieve Montero
    Department of Molecular Biology and Chemistry, Simon Fraser University, 8888 University Drive, Burnaby V5A 1S6, British Columbia, Canada
    Microbiol Mol Biol Rev 72:54-84, table of contents. 2008
    ..In addition, emerging approaches to vaccine design are presented...
  38. ncbi Protein design of an HIV-1 entry inhibitor
    M J Root
    Howard Hughes Medical Institute, Whitehead Institute for Biomedical Research, Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
    Science 291:884-8. 2001
    ..The inhibitory activity of 5-Helix also suggests a strategy for generating an HIV-1 neutralizing antibody response that targets the carboxyl-terminal region of the gp41 ectodomain...
  39. ncbi Model for the structure of the HIV gp41 ectodomain: insight into the intermolecular interactions of the gp41 loop
    M Caffrey
    Department of Biochemistry and Molecular Biology, University of Illinois at Chicago, Chicago, IL 60612, USA
    Biochim Biophys Acta 1536:116-22. 2001
    ..17 (1998) 4572--4584). The resulting model presents the first structural information for the HIV gp41 loop, which has been implicated to play a direct role in binding to gp120 and C1q of the complement system...
  40. ncbi A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein
    M Lu
    Howard Hughes Medical Institute, Whitehead Institute for Biomedical Research, Department of Biology, Massachusetts Institute of Technology, Cambridge 02142, USA
    J Biomol Struct Dyn 15:465-71. 1997
    ..Our results also provide strong support for the notion that short peptides can form unique, cooperatively folded subdomains, in which elements of secondary structure are stabilized by native-like tertiary interactions...
  41. pmc Human immunodeficiency virus type 1 Env with an intersubunit disulfide bond engages coreceptors but requires bond reduction after engagement to induce fusion
    L G Abrahamyan
    Department of Molecular Biophysics and Physiology, Rush Medical College, Chicago, Illinois 60612, USA
    J Virol 77:5829-36. 2003
    ..The capture of this configuration of Env could yield a suitable antigen for vaccine development, and it may also be a target for pharmacological intervention against HIV-1 entry...
  42. ncbi Pharmacokinetics of sifuvirtide, a novel anti-HIV-1 peptide, in monkeys and its inhibitory concentration in vitro
    Shu jia Dai
    Laboratory of Metabolism of Biotechnology Derived Drugs, Beijing Institute of Radiation Medicine, Beijing 100850, China
    Acta Pharmacol Sin 26:1274-80. 2005
    ..To study the pharmacokinetics of sifuvirtide, a novel anti-human immunodeficiency virus (HIV) peptide, in monkeys and to compare the inhibitory concentrations of sifuvirtide and enfuvirtide on HIV-1-infected-cell fusion...
  43. pmc A V3 loop-dependent gp120 element disrupted by CD4 binding stabilizes the human immunodeficiency virus envelope glycoprotein trimer
    Shi Hua Xiang
    Dana Farber Cancer Institute, 44 Binney Street, CLS 1010, Boston, MA 02115, USA
    J Virol 84:3147-61. 2010
    ..CD4 binding dismantles this element, altering the gp120-gp41 relationship and rendering the hydrophobic patch in the V3 tip available for chemokine receptor binding...
  44. pmc Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41
    M B Zwick
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 75:10892-905. 2001
    ..g., subtypes B, C, and E). The results suggest that a rather extensive region of gp41 close to the transmembrane domain is accessible to neutralizing Abs and could form a useful target for vaccine design...
  45. pmc Structure-guided alterations of the gp41-directed HIV-1 broadly neutralizing antibody 2F5 reveal new properties regarding its neutralizing function
    Javier Guenaga
    IAVI Neutralizing Antibody Center at The Scripps Research Institute, La Jolla, California, United States of America
    PLoS Pathog 8:e1002806. 2012
    ..The data suggest a new mechanism of action, important for vaccine design, in which the 2F5 CDRH3 contacts and destabilizes the MPER helix downstream of its core epitope to allow induction of the extended-loop conformation...
  46. doi Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site
    Jean Philippe Julien
    Department of Biochemistry, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada M5S 1A8
    J Mol Biol 384:377-92. 2008
    ....
  47. doi Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges
    Morgane Bomsel
    Mucosal Entry of HIV 1 and Mucosal Immunity, Cell Biology and Host Pathogen Interactions Department, Cochin Institute, CNRS UMR 8104, 22 rue Mechain, Paris, France
    Immunity 34:269-80. 2011
    ..The protection observed challenges the paradigm whereby circulating antiviral antibodies are required for protection against HIV-1 infection and may serve in designing a human vaccine against HIV-1-AIDS...
  48. pmc Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions
    James M Binley
    Departments of Immunology and Molecular Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Virol 77:5678-84. 2003
    ..Overall, this disulfide-shackled virus is a unique tool with potential utility in vaccine design, drug discovery, and elucidation of the HIV-1 entry process...
  49. pmc Maturation-induced cloaking of neutralization epitopes on HIV-1 particles
    Amanda S Joyner
    Department of Microbiology and Immunology, Vanderbilt University School of Medicine, Nashville, Tennessee, USA
    PLoS Pathog 7:e1002234. 2011
    ..Masking of neutralization-sensitive epitopes during particle maturation may contribute to HIV-1 immune evasion and has practical implications for vaccine strategies targeting the gp41 MPER...
  50. pmc The cytoplasmic domain of the HIV-1 glycoprotein gp41 induces NF-κB activation through TGF-β-activated kinase 1
    Thomas S Postler
    New England Primate Research Center, Department of Microbiology and Molecular Genetics, Harvard Medical School, Southborough, MA 01772 9102, USA
    Cell Host Microbe 11:181-93. 2012
    ..These findings demonstrate an evolutionarily conserved role for gp41CD in activating NF-κB to promote infection...
  51. pmc Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion
    Gary Frey
    Department of Biological Chemistry and Molecular Pharmacology, Harvard Medical School, 250 Longwood Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:13938-43. 2006
    ..They bind in a highly conserved, hydrophobic pocket on the inner core of the gp41 trimer, a region previously identified as a potential inhibitor site...
  52. pmc Structural basis of HIV-1 neutralization by affinity matured Fabs directed against the internal trimeric coiled-coil of gp41
    Elena Gustchina
    Laboratory of Chemical Physics, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 6:e1001182. 2010
    ....
  53. pmc Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates
    Franky Baatz
    Laboratory of Retrovirology, CRP Sante, Luxembourg, Luxembourg
    PLoS ONE 6:e21535. 2011
    ....
  54. pmc Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications
    Steve Bryson
    Department of Biochemistry, University of Toronto, 1 King s College Circle, Toronto, Ontario, Canada M5S 1A8
    J Virol 83:11862-75. 2009
    ..Based on our results, we propose a somewhat more flexible molecular model of epitope recognition by bnMAb 2F5, which could guide future attempts at designing small-molecule MPER-like vaccines capable of eliciting 2F5-like antibodies...
  55. pmc Highly conserved structural properties of the C-terminal tail of HIV-1 gp41 protein despite substantial sequence variation among diverse clades: implications for functions in viral replication
    Jonathan D Steckbeck
    Center for Vaccine Research, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15261, USA
    J Biol Chem 286:27156-66. 2011
    ....
  56. pmc Role of HIV membrane in neutralization by two broadly neutralizing antibodies
    S Munir Alam
    Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 106:20234-9. 2009
    ..These results bear directly on strategies for rational design of HIV-1 envelope immunogens...
  57. pmc Maturation-dependent human immunodeficiency virus type 1 particle fusion requires a carboxyl-terminal region of the gp41 cytoplasmic tail
    Jiyang Jiang
    Department of Microbiology and Immunology, Vanderbilt University School of Medicine, A 5301 Medical Center North, Nashville, TN 37232 2363, USA
    J Virol 81:9999-10008. 2007
    ..They further indicate that the stable association of gp41 with Gag in immature virions is not sufficient for inhibition of immature HIV-1 particle fusion...
  58. doi HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis
    D Tudor
    Entrée Muqueuse du VIH et Immunité Muqueuse, Mucosal Entry of HIV 1 and Mucosal Immunity, Departement de Biologie Cellulaire, Cell Biology Department, Institut Cochin, Universite Paris Descartes, CNRS UMR 8104, Paris, France
    Mucosal Immunol 2:412-26. 2009
    ..This analysis of HEPS monoclonal IgA gives a unique opportunity to correlate an antibody function (resistance to a pathogen in vivo) with an antibody gene. Such neutralizing monoclonal IgAs could be used in microbicide formulation...
  59. pmc Novel recombinant engineered gp41 N-terminal heptad repeat trimers and their potential as anti-HIV-1 therapeutics or microbicides
    Xi Chen
    School of Life Sciences, Tsinghua University, Beijing 100084, China
    J Biol Chem 285:25506-15. 2010
    ..Therefore, N28Fd trimer has great potentials for further development as an affordable therapeutic or microbicide for treatment and prevention of HIV-1 infection...
  60. pmc NK cytotoxicity against CD4+ T cells during HIV-1 infection: a gp41 peptide induces the expression of an NKp44 ligand
    Vincent Vieillard
    Laboratoire d Immunologie Cellulaire et Tissulaire, Institut National de la Sante et de la Recherche Medicale U543, Hopital Pitie Salpetriere, 75013 Paris, France
    Proc Natl Acad Sci U S A 102:10981-6. 2005
    ..Understanding this mechanism may help to develop future therapeutic strategies and vaccines against HIV-1 infection...
  61. pmc Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity
    Tsutomu Murakami
    Department of Immunology, Graduate School and Faculty of Medicine, University of the Ryukyus, Nishihara, Okinawa 903 0215, Japan
    J Virol 78:1026-31. 2004
    ..Interestingly, truncation of the gp41 cytoplasmic tail reversed the fusion defect. These results suggest that interactions between unprocessed Gag and the gp41 cytoplasmic tail suppress fusion...
  62. pmc Crystal structure and size-dependent neutralization properties of HK20, a human monoclonal antibody binding to the highly conserved heptad repeat 1 of gp41
    Charles Sabin
    Unit of Virus Host Cell Interactions, UMI 3265, Université Joseph Fourier EMBL CNRS, Grenoble, France
    PLoS Pathog 6:e1001195. 2010
    ....
  63. ncbi Interaction of endocytic signals from the HIV-1 envelope glycoprotein complex with members of the adaptor medium chain family
    H Ohno
    Cell Biology and Metabolism Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland 20892, USA
    Virology 238:305-15. 1997
    ..These observations suggest that HIV-1 Env utilizes the protein sorting machinery of the host cells for internalization and sorting at various steps of the endocytic and biosynthetic pathways...
  64. pmc Direct antibody access to the HIV-1 membrane-proximal external region positively correlates with neutralization sensitivity
    B K Chakrabarti
    IAVI Neutralizing Antibody Center at TSRI, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Virol 85:8217-26. 2011
    ....
  65. ncbi A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1
    G Stiegler
    Institute of Applied Microbiology, University of Agricultural Sciences, A 1190 Vienna, Austria
    AIDS Res Hum Retroviruses 17:1757-65. 2001
    ..Moreover, our results suggest that 4E10 should be further investigated for passive anti-HIV immunotherapy...
  66. pmc Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface
    Likai Song
    Cancer Vaccine Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 106:9057-62. 2009
    ..HIV-1 MPER features important for targeted vaccine design have been revealed, the implications of which extend to BNAb targets on other viral fusion proteins...
  67. pmc Resistance to CCR5 inhibitors caused by sequence changes in the fusion peptide of HIV-1 gp41
    Cleo G Anastassopoulou
    Department of Microbiology and Immunology, Weill Medical College of Cornell University, 1300 York Avenue, New York, NY 10021, USA
    Proc Natl Acad Sci U S A 106:5318-23. 2009
    ..Together, the experimental results and theoretical model may help understand how HIV-1 uses CCR5 to enter target cells under various conditions...
  68. pmc A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies
    Gary Frey
    Laboratory of Molecular Medicine, Children s Hospital, and Department of Pediatrics, Harvard Medical School, 320 Longwood Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 105:3739-44. 2008
    ..These results help explain the rarity of 2F5- and 4E10-like antibody responses and suggest a strategy for eliciting them...
  69. pmc In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth
    Xiaoying Shen
    Duke Human Vaccine Institute, Duke University Medicine Center, Durham, NC 27710, USA
    J Virol 83:3617-25. 2009
    ..Our findings suggest that multiple events (i.e., genetic predisposition and HIV-1 immune dysregulation) may be required for induction of broadly reactive gp41 MPER antibodies in natural infection...
  70. pmc Single-particle cryoelectron microscopy analysis reveals the HIV-1 spike as a tripod structure
    Shang Rung Wu
    Department of Biosciences and Nutrition, Karolinska Institute, S 141 83 Huddinge, Sweden
    Proc Natl Acad Sci U S A 107:18844-9. 2010
    ..The loop displacements probably prepared the spike for coreceptor interaction and roof opening so that a new fusion-active gp41 structure, assembled at the center of the cage bottom, could reach the target membrane...
  71. pmc Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution
    Xiaoying Shen
    Department of Surgery, Duke Human Vaccine Institute, Duke University, Durham, NC 27710, USA
    Proc Natl Acad Sci U S A 107:5972-7. 2010
    ..These data suggest that a major contribution to the L669S mutant virus phenotype of enhanced susceptibility to MPER mAbs is prolonged exposure of the MPER neutralizing epitope during viral entry...
  72. pmc Electron tomography of the contact between T cells and SIV/HIV-1: implications for viral entry
    Rachid Sougrat
    Laboratory of Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, United States of America
    PLoS Pathog 3:e63. 2007
    ..Determination of the molecular composition and structure of the entry claw may facilitate the identification of improved drugs for the inhibition of HIV-1 entry...
  73. pmc Immunogenicity of recombinant human immunodeficiency virus type 1-like particles expressing gp41 derivatives in a pre-fusion state
    Mikyung Kim
    Laboratory of Immunobiology, Department of Medical Oncology, Dana Farber Cancer Institute and Department of Medicine, Harvard Medical School, Boston, MA 02115, United States
    Vaccine 25:5102-14. 2007
    ..In addition, the anti-gp41 immune response was preferentially directed to the C-helical domain, away from the MPER. Future vaccine design needs to contend with the complexity of epitope display as well as immunodominance...
  74. ncbi Endocytosis of endogenously synthesized HIV-1 envelope protein. Mechanism and role in processing for association with class II MHC
    J F Rowell
    Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
    J Immunol 155:473-88. 1995
    ....
  75. ncbi The membrane-proximal tryptophan-rich region of the HIV glycoprotein, gp41, forms a well-defined helix in dodecylphosphocholine micelles
    D J Schibli
    Department of Biological Sciences, University of Calgary, Alberta, Canada
    Biochemistry 40:9570-8. 2001
    ..This work shows that the Trp-rich membrane-proximal region of HIV and related viruses can bind to the surfaces of zwitterioninc membranes in a "Velcro-like" manner...
  76. pmc Role of hydrophobic residues in the central ectodomain of gp41 in maintaining the association between human immunodeficiency virus type 1 envelope glycoprotein subunits gp120 and gp41
    Joanne York
    Montana Biotechnology Center, The University of Montana, Missoula, Montana 59812, USA
    J Virol 78:4921-6. 2004
    ..These envelope glycoproteins readily shed their gp120 and are unable to mediate cell-cell fusion. These findings suggest an important role for the conserved bulky hydrophobic residues in stabilizing the gp120-gp41 complex...
  77. ncbi In vivo efficacy of anti-glycoprotein 41, but not anti-glycoprotein 120, immunotoxins in a mouse model of HIV infection
    Seth H Pincus
    Department of Microbiology and Animal Resources Center, Montana State University, Bozeman, MT 59717, USA
    J Immunol 170:2236-41. 2003
    ..These data support continued exploration of the utility of ITs for HIV infection, particularly the use of anti-gp41 ITs in combination with soluble CD4 derivatives...
  78. ncbi Monoclonal antibodies that bind to the core of fusion-active glycoprotein 41
    C H Chen
    Department of Microbiology, Meharry Medical College, Nashville, Tennessee 37208, USA
    AIDS Res Hum Retroviruses 16:2037-41. 2000
    ..Antibodies that are able to interact with the core of the putative fusion-active gp41 may be useful in further unveiling the mechanism of HIV-induced membrane fusion...
  79. pmc Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein
    Wei Huang
    Monogram Biosciences, 345 Oyster Point Blvd, South San Francisco, CA 94080, USA
    J Virol 82:5584-93. 2008
    ..We hypothesize that the latter plays an important role in the transition from CCR5 to CXCR4 coreceptor use...
  80. pmc Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation
    P Poignard
    Centre d immunologie de Marseille Luminy, France
    J Exp Med 183:473-84. 1996
    ....
  81. pmc HIV-1 resistance to CCR5 antagonists associated with highly efficient use of CCR5 and altered tropism on primary CD4+ T cells
    Jennifer M Pfaff
    Department of Microbiology, University of Pennsylvania, 3610 Hamilton Walk, Philadelphia, PA 19104, USA
    J Virol 84:6505-14. 2010
    ....
  82. ncbi Membrane expression of HIV envelope glycoproteins triggers apoptosis in CD4 cells
    A G Laurent-Crawford
    Institut Pasteur, Department of AIDS and Retroviruses, UA CNRS 1157, Paris, France
    AIDS Res Hum Retroviruses 9:761-73. 1993
    ..Therefore, cell death during HIV infection in CD4+ lymphocyte cultures is due to a specific event triggered by the gp120-gp41 heterodimer complex programming death in metabolically active cells...
  83. pmc Analysis of the human immunodeficiency virus type 1 gp41 membrane proximal external region arrayed on hepatitis B surface antigen particles
    S Phogat
    Structural Virology Section, Vaccine Research Center, NIAID, NIH, Bethesda, MD 20892 3005, USA
    Virology 373:72-84. 2008
    ..The first generation HBsAg-MPER particles represent a unique means to present HIV-1 envelope glycoprotein neutralizing determinants to the immune system...
  84. ncbi HIV-1 neutralization: mechanisms and relevance to vaccine design
    Michael B Zwick
    Department of Immunology, The Scripps Research Institute, La Jolla, California 92037, USA
    Curr HIV Res 5:608-24. 2007
    ....
  85. pmc Human immunodeficiency virus type 1 gp41 antibodies that mask membrane proximal region epitopes: antibody binding kinetics, induction, and potential for regulation in acute infection
    S Munir Alam
    Human Vaccine Institute, Box 3258, Duke University Medical Center, MSRBII Bldg, Room 4042, Durham, NC 27710, USA
    J Virol 82:115-25. 2008
    ....
  86. pmc Induction of mucosal and systemic neutralizing antibodies against human immunodeficiency virus type 1 (HIV-1) by oral immunization with bovine Papillomavirus-HIV-1 gp41 chimeric virus-like particles
    Hongtao Zhang
    Department of Microbiology and Immunology, Stritch School of Medicine, Loyola University Chicago, Maywood, IL 60153, USA
    J Virol 78:8342-8. 2004
    ..Importantly, the sera and fecal extracts from mice orally immunized with the CVLPs neutralized HIV-1(MN) in vitro. Thus, BPV-HIV-1 gp41 CVLPs may be used to prevent and to treat HIV-1 infection...
  87. pmc Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment
    Stefano Menzo
    Istituto di Microbiologia e Scienze Biomediche, Universita Politecnica delle Marche, Ancona, Italy
    Antimicrob Agents Chemother 48:3253-9. 2004
    ....
  88. pmc In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1
    Daniel P Leaman
    Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA 92037, USA
    J Virol 84:3382-95. 2010
    ..Heterogeneity in Env from endogenous and exogenous sources might also subvert humoral immunity to HIV-1, so in-solution VCAs may help to dissect this heterogeneity for vaccine design purposes...
  89. ncbi Induction of neutralizing antibody against human immunodeficiency virus type 1 (HIV-1) by immunization with gp41 membrane-proximal external region (MPER) fused with porcine endogenous retrovirus (PERV) p15E fragment
    Min Luo
    Department of Cell Biology and Genetics, The College of Life Sciences, No 5 Yi He Yuan Road, Peking University, Beijing 100871, China
    Vaccine 24:435-42. 2006
    ..These results offer a new strategy for HIV-1 vaccine design and development targeting the gp41 MPER...
  90. pmc Depletion of latent HIV-1 infection in vivo: a proof-of-concept study
    Ginger Lehrman
    University of Texas Southwestern Medical Center at Dallas, Department of Medicine, Division of Infectious Diseases, 5323 Harry Hines Boulevard, Dallas, TX 753901, USA
    Lancet 366:549-55. 2005
    ..Since the chromatin remodeling enzyme histone deacetylase 1 (HDAC1) maintains latency of integrated HIV, we tested the ability of the HDAC inhibitor valproic acid to deplete persistent, latent infection in resting CD4+ T cells...
  91. pmc Distinct conformational states of HIV-1 gp41 are recognized by neutralizing and non-neutralizing antibodies
    Gary Frey
    Division of Molecular Medicine, Children s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Nat Struct Mol Biol 17:1486-91. 2010
    ..These results have important implications for gp41-based vaccine design...
  92. pmc Detailed mechanistic insights into HIV-1 sensitivity to three generations of fusion inhibitors
    Dirk Eggink
    Laboratory of Experimental Virology, Department of Medical Microbiology, Center for Infection and Immunity Amsterdam, Academic Medical Center of the University of Amsterdam, 1105 AZ Amsterdam, The Netherlands
    J Biol Chem 284:26941-50. 2009
    ..Implications for the design of novel antiviral peptide inhibitors are discussed...
  93. pmc Epitope specificities of broadly neutralizing plasmas from HIV-1 infected subjects
    D Noah Sather
    Seattle Biomedical Research Institute, Seattle, WA 98109, United States
    Vaccine 28:B8-12. 2010
    ..Overall, our study indicates that more than one pathway leads to the development of broad cross-reactive NAbs during HIV-infection...
  94. pmc Structural characterization of HIV gp41 with the membrane-proximal external region
    Wuxian Shi
    Center for Synchrotron Biosciences, Case Western Reserve University, Cleveland, OH 44106, USA
    J Biol Chem 285:24290-8. 2010
    ....
  95. ncbi Neutralizing as well as non-neutralizing polyclonal immunoglobulin (Ig)G from infected patients capture HIV-1 via antibodies directed against the principal immunodominant domain of gp41
    Renaud Burrer
    EA3770, Institut de Virologie, Universite Louis Pasteur, 67000 Strasbourg, France
    Virology 333:102-13. 2005
    ..Thus, capture assays, including the immune complex capture assay that is more representative of "physiological" conditions, cannot be used as surrogate method for the investigation of the neutralizing activity of Abs...
  96. pmc Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies
    S Gnanakaran
    Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, New Mexico, USA
    PLoS Comput Biol 6:e1000955. 2010
    ..Five sites were in the CD4-induced coreceptor binding site of gp120, suggesting an important role for this region in the elicitation of broadly neutralizing antibody responses against HIV-1...
  97. doi Characterization of a trimeric MPER containing HIV-1 gp41 antigen
    Andreas Hinz
    Unit for Virus Host Cell Interaction, UMI 3265 UJF EMBL CNRS, 6 rue Jules Horowitz, 38042 Grenoble Cedex 9, France
    Virology 390:221-7. 2009
    ..Thus trimerisation of MPER regions does not suffice to induce a potent neutralizing antibody response specific for conserved regions within gp41...
  98. pmc A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 infected individuals
    Laura M Walker
    Department of Immunology and Microbial Science and IAVI Neutralizing Antibody Center, The Scripps Research Institute, La Jolla, California, United States of America
    PLoS Pathog 6:e1001028. 2010
    ..In approximately half of the donors, key N-linked glycans were critical for expression of the epitopes recognized by the bNAb specificities in the sera...
  99. pmc Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C
    James M Binley
    Torrey Pines Institute for Molecular Studies, 3550 General Atomics Court, San Diego, California 92121, USA
    J Virol 82:11651-68. 2008
    ....
  100. pmc Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region
    Elin S Gray
    AIDS Virus Research Unit, National Institute for Communicable Diseases, Johannesburg, South Africa
    J Virol 83:11265-74. 2009
    ..Nevertheless, the identification of three novel antibody specificities within the MPER supports its further study as a promising target for vaccine design...
  101. pmc Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1
    Michael B Zwick
    Department of Immunology IMM 2, The Scripps Research Institute, 10550 North Torrey Pines Rd, La Jolla, CA 92037, USA
    J Virol 79:1252-61. 2005
    ..Neutralization experiments showing synergy between and T20 and 4E10 against HIV-1 are also presented. The data presented may aid in the design of antigens that better present the MPER of gp41 to the immune system...

Research Grants151 found, 100 shown here

  1. Preventing the Establishment of Enfuvirtide-resistance in the Latent Reservoir
    Steven Deeks; Fiscal Year: 2007
    ..Also, we believe that insights regarding the mechanisms operative in elite controllers will prove to be highly informative for future efforts aimed at preventing HIV infection and eradicating virus in those already infected. ..
  2. Coreceptor Modulation of TCR-MHC Interactions
    S Alam; Fiscal Year: 2003
    ..abstract_text> ..
  3. SARS-CoV S Protein Receptor-binding Domain-based Vaccines
    Shibo Jiang; Fiscal Year: 2010
    ..The long-term goal of this project is to develop highly effective and safe subunit vaccines for protecting at-risk populations from SARS-CoV infection or bioterrorism attack. ..
  4. Rational Design of HIV Fusion Inhibitors Targeting gp41
    Shibo Jiang; Fiscal Year: 2007
    ..Therefore, this research is relevant to public health. [unreadable] [unreadable] [unreadable]..
  5. RATIONAL DESIGN OF ANTIVIRAL COMPOUNDS TO THE GP41 CORE
    Shibo Jiang; Fiscal Year: 2002
    ..The long-term goal is to develop novel anti-HIV-1 drugs for chemotherapy of HIV-1 infection and AIDS. ..
  6. RATIONAL DESIGN OF ANTIVIRAL COMPOUNDS TO THE GP41 CORE
    Shibo Jiang; Fiscal Year: 2003
    ..The long-term goal is to develop novel anti-HIV-1 drugs for chemotherapy of HIV-1 infection and AIDS. ..
  7. SARS-CoV S Protein Receptor-binding Domain-based Vaccines
    Shibo Jiang; Fiscal Year: 2009
    ..The long-term goal of this project is to develop highly effective and safe subunit vaccines for protecting at-risk populations from SARS-CoV infection or bioterrorism attack. ..
  8. RATIONAL DESIGN OF ANTIVIRAL COMPOUNDS TO THE GP41 CORE
    Shibo Jiang; Fiscal Year: 2000
    ..The long-term goal is to develop novel anti-HIV-1 drugs for chemotherapy of HIV-1 infection and AIDS. ..
  9. SARS-CoV S Protein Receptor-binding Domain-based Vaccines
    Shibo Jiang; Fiscal Year: 2007
    ..The long-term goal of this project is to develop highly effective and safe subunit vaccines for protecting at-risk populations from SARS-CoV infection or bioterrorism attack. ..
  10. Rational Design of HIV Fusion Inhibitors Targeting gp41
    Shibo Jiang; Fiscal Year: 2010
    ..Therefore, this research is relevant to public health. ..
  11. Rational Design of HIV Fusion Inhibitors Targeting gp41
    Shibo Jiang; Fiscal Year: 2006
    ..Therefore, this research is relevant to public health. [unreadable] [unreadable] [unreadable]..
  12. SARS-CoV S Protein Receptor-binding Domain-based Vaccines
    Shibo Jiang; Fiscal Year: 2008
    ..The long-term goal of this project is to develop highly effective and safe subunit vaccines for protecting at-risk populations from SARS-CoV infection or bioterrorism attack. ..
  13. Rational Design of HIV Fusion Inhibitors Targeting gp41
    Shibo Jiang; Fiscal Year: 2009
    ..Therefore, this research is relevant to public health. ..
  14. Anti-HIV-1 Composite Cellulose Acetate Phthalate Film
    Shibo Jiang; Fiscal Year: 2008
    ....
  15. Multivalent gp41 Peptides as Novel Immunogens
    Lai Xi Wang; Fiscal Year: 2004
    ..The structure-immunogenicity relationships will be evaluated. It is expected that the proposed studies will yield important new data with significant relevance to the development of an effective HIV-1 vaccine. ..
  16. Targeting neutralizing antibody-defined sites on HIV gp41 for vaccine design
    Michael Zwick; Fiscal Year: 2008
    ..In these ways, antibody access to the MPER and NHR region of gp41 will be precisely evaluated, which in turn should lead to improved gp41-based immunogens that will elicit more potent neutralizing Abs against HIV-1. ..
  17. Engineering and sorting HIV-1 display Env libraries for vaccine design
    Michael Zwick; Fiscal Year: 2008
    ..Inactivated forms of such mutant viruses may elicit more effective immune (antibody) responses and may therefore lead to better vaccines against HIV/AIDS. ..
  18. Novel Vaccine Targeting the Sugar Coat of HIV-1
    Lai Xi Wang; Fiscal Year: 2004
    ..The synthetic conjugate-vaccine will be used to immunize mice. The immune responses will be analyzed using ELISAs and virus neutralization assays. ..
  19. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2004
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. ..
  20. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2007
    ..Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs. ..
  21. NEUTRALIZING ANTIBODIES AGAINST ORTHOPOX VIRUSES
    Dennis Burton; Fiscal Year: 2004
    ..To examine the impact of passive immunization in immunoprophylaxis and immunotherapy of a smallpox-like disease in a non-human primate model, we will use an experimental model of monkeypox virus infection ..
  22. COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIV
    Dennis Burton; Fiscal Year: 2004
    ..This will provide us with the first opportunity to look at the effects of potent human mAbs on established infection in the presence of functional T cells. ..
  23. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2004
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. ..
  24. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2004
    ....
  25. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2008
    ..Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs. ..
  26. ANTIBODIES AGAINST HIV-1 gp41: TOOLS FOR VACCINE DESIGN
    Michael Zwick; Fiscal Year: 2005
    ..A panel of mAbs against the described epitopes on gp41 will provide valuable tools to aid in HIV-1 vaccine design. ..
  27. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2005
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. ..
  28. Enzymatic Transglycosylation for N-Glycopeptide Synthesis
    Lai Xi Wang; Fiscal Year: 2007
    ..In the long term, the proposed studies will contribute to the development of glycoprotein-based drugs. [unreadable] [unreadable] [unreadable]..
  29. Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins
    Lai Xi Wang; Fiscal Year: 2007
    ..The knowledge gained from the proposed research will eventually facilitate the development of glycoprotein-based therapeutics. ..
  30. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2007
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. [unreadable] [unreadable] [unreadable]..
  31. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2007
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. [unreadable] [unreadable] [unreadable]..
  32. HIV-1 Glycopeptides as Immunogens
    Lai Xi Wang; Fiscal Year: 2007
    ..The proposed research attempts to raise broadly neutralizing antibodies through novel immunogen design. The research will yield important new data with direct relevance to HIV-1 vaccine development. [unreadable] [unreadable]..
  33. Targeting neutralizing antibody-defined sites on HIV gp41 for vaccine design
    Michael Zwick; Fiscal Year: 2007
    ..In these ways, antibody access to the MPER and NHR region of gp41 will be precisely evaluated, which in turn should lead to improved gp41-based immunogens that will elicit more potent neutralizing Abs against HIV-1. ..
  34. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2001
    ....
  35. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2006
    ..Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs. ..
  36. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2006
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. [unreadable] [unreadable] [unreadable]..
  37. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2007
    ..There is widespread agreement that an HIV vaccine will need to trigger such a response to be fully effective. [unreadable] [unreadable] [unreadable]..
  38. IMMUNOFOCUSING TO A NEUTRALIZING EPITOPE ON GP120
    Dennis Burton; Fiscal Year: 2006
    ..Immunization with this molecule should, in principle, be akin to immunizing with the footprint of b12. [unreadable] [unreadable] [unreadable]..
  39. Probing the germlines of broadly neutralizing anti-HIV antibodies in knockin mice
    Dennis Burton; Fiscal Year: 2008
    ..It is expected to generate valuable reagents and animals for the proposed UO1 consortium. ..
  40. THE HUMAN ANTIBODY RESPONSE TO METAPNEUMOVIRUS: PROPHYLAXIS AND VACCINE DESIGN
    Dennis Burton; Fiscal Year: 2008
    ..Such antibodies will be positioned for immediate clinical development as passive prophylactic agents for the prevention of HMPV disease in vulnerable patient cohorts. ..
  41. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2005
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. ..
  42. COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIV
    Dennis Burton; Fiscal Year: 2005
    ..This will provide us with the first opportunity to look at the effects of potent human mAbs on established infection in the presence of functional T cells. ..
  43. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2005
    ..Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs. ..
  44. VIRAL EVASION AND HIV ENTRY-BLOCKING STRATEGIES
    Dennis Burton; Fiscal Year: 2004
    ..The studies will reveal how HIV-1 can evade entry-blocking strategies, and may provide important information for vaccine design. ..
  45. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 2009
    ..Both aims are focused on providing the tools that will eventually allow us to generate or design immunogens that reliably elicit broadly neutralizing Abs. ..
  46. ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPPL-SCID
    Dennis Burton; Fiscal Year: 1999
    ..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
  47. Targeting neutralizing antibody-defined sites on HIV gp41 for vaccine design
    Michael Zwick; Fiscal Year: 2009
    ..In these ways, antibody access to the MPER and NHR region of gp41 will be precisely evaluated, which in turn should lead to improved gp41-based immunogens that will elicit more potent neutralizing Abs against HIV-1. ..
  48. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2002
    ....
  49. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis Burton; Fiscal Year: 1993
    ..The research will provide opportunities to explore the mechanism(s) responsible for virus neutralization and some of the rules governing antibody recognition of viral antigens...
  50. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2000
    ....
  51. THE HUMAN ANTIBODY RESPONSE TO METAPNEUMOVIRUS: PROPHYLAXIS AND VACCINE DESIGN
    Dennis Burton; Fiscal Year: 2009
    ..Such antibodies will be positioned for immediate clinical development as passive prophylactic agents for the prevention of HMPV disease in vulnerable patient cohorts. ..
  52. Probing the antibody response to HCV to facilitate rational immunogen design
    Dennis R Burton; Fiscal Year: 2010
    ..We propose to develop antibody-inducing vaccine candidates against HCV. A key feature of our work is the rational design of vaccine candidates based on countering some of the tricks that this virus uses to evade antibodies. ..
  53. COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIV
    Dennis Burton; Fiscal Year: 2002
    ..This will provide us with the first opportunity to look at the effects of potent human mAbs on established infection in the presence of functional T cells. ..
  54. THE ANTIVIRAL ACTIVITY OF ANTIBODIES TO A FILOVIRUS
    Dennis Burton; Fiscal Year: 2003
    ....
  55. ANTIBODY EFFECTOR FUNCTION IN PROTECTION AGAINST HIV-1
    Dennis Burton; Fiscal Year: 2003
    ..The results will help clarify how antibodies protect against HIV and may have implications for vaccine design and microbicide development. ..
  56. COOPERATIVE HUMORAL & CELLULAR IMMUNITY AGAINST HIV/SIV
    Dennis Burton; Fiscal Year: 2003
    ..This will provide us with the first opportunity to look at the effects of potent human mAbs on established infection in the presence of functional T cells. ..
  57. Targeting neutralizing antibody-defined sites on HIV gp41 for vaccine design
    Michael B Zwick; Fiscal Year: 2010
    ..In these ways, antibody access to the MPER and NHR region of gp41 will be precisely evaluated, which in turn should lead to improved gp41-based immunogens that will elicit more potent neutralizing Abs against HIV-1. ..
  58. THE HUMAN ANTIBODY RESPONSE TO METAPNEUMOVIRUS: PROPHYLAXIS AND VACCINE DESIGN
    Dennis R Burton; Fiscal Year: 2010
    ..Such antibodies will be positioned for immediate clinical development as passive prophylactic agents for the prevention of HMPV disease in vulnerable patient cohorts. ..
  59. Probing the antibody response to HCV to facilitate rational immunogen design
    Dennis Burton; Fiscal Year: 2009
    ..We propose to develop antibody-inducing vaccine candidates against HCV. A key feature of our work is the rational design of vaccine candidates based on countering some of the tricks that this virus uses to evade antibodies. ..
  60. ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCID
    Dennis Burton; Fiscal Year: 2000
    ..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
  61. HUMAN ANTIBODIES TO HIV-1 BY REPERTOIRE CLONING
    Dennis R Burton; Fiscal Year: 2010
    ..PUBLIC HEALTH RELEVANCE: An optimal HIV vaccine will likely elicit broadly neutralizing antibodies. This application seeks to understand broad neutralization at the molecular level to permit the design of such a vaccine. ..
  62. ANTI-HIV ANTIBODY IMMUNOTHERAPY IN HUPBL-SCID
    Dennis Burton; Fiscal Year: 2001
    ..The emerging results should assist in the design of immunotherapeutic strategies using neutralizing antibodies and illuminate areas of potential concern such as neutralization escape. ..
  63. HIV-1 Gene Suppression by CD8+T Cell
    Georgia Tomaras; Fiscal Year: 2005
    ..These studies will further our understanding of this potent means of virologic control and promote the development of this host cellular immune response in future therapeutic and vaccination strategies. ..
  64. UAB AIEDRP: Immune Control and Escape in Acute Infection
    JOHN KILBY; Fiscal Year: 2006
    ..Finally, our proposal involves collaborations with other AIEDRP units where an important exchange of patient specimens, scientific expertise, technology, and data will continue. ..
  65. HIV-1 Gene Suppression by CD8+T Cell
    Georgia Tomaras; Fiscal Year: 2004
    ..These studies will further our understanding of this potent means of virologic control and promote the development of this host cellular immune response in future therapeutic and vaccination strategies. ..
  66. NCRR FACSAria Cell Sorter
    Barton Haynes; Fiscal Year: 2004
    ..Advisory committees, institutional support, financial support for continued maintenance, and management plans are in place to insure that the instrument will be fully and appropriately utilized. ..
  67. HIV-1 Gene Suppression by CD8+ T Cells
    Georgia Tomaras; Fiscal Year: 2008
    ..The results from this study will determine if induction of noncytolytic CD8 T cells would be beneficial in a protective vaccination strategy or whether it should be restricted to disease-modifying vaccine strategies. ..
  68. ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120
    Abraham Pinter; Fiscal Year: 2009
    ....
  69. HIV-1 Glycopeptides as Immunogens
    Lai Xi Wang; Fiscal Year: 2008
    ..Theproposed research attempts to raise broadly neutralizing antibodies through novel immunogen design. Theresearch willyield important new data with direct relevance to HIV-1 vaccine development. ..
  70. HIV-1 Glycopeptides as Immunogens
    Lai Xi Wang; Fiscal Year: 2009
    ..Theproposed research attempts to raise broadly neutralizing antibodies through novel immunogen design. Theresearch willyield important new data with direct relevance to HIV-1 vaccine development. ..
  71. ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120
    Abraham Pinter; Fiscal Year: 2010
    ....
  72. Impact of maternal HAART on HIV-infected breastfeeding infants: Malawi
    Susan H Eshleman; Fiscal Year: 2010
    ..We will determine whether initiation of treatment in breastfeeding women poses any risk to breastfeeding infants who are HIV-infected, by inducing resistance to antiretroviral drugs in the infant's virus. ..
  73. Long-Acting HIV Therapy for Injection Drug Users
    Jeffrey M Jacobson; Fiscal Year: 2010
    ..We propose a novel treatment strategy involving systemic administration of long-acting antiretroviral therapy as a means to ensure effective drug delivery and viral suppression in HIV-infected populations prone to poor drug-adherence. ..
  74. Invasion of C. neoformans into brain endothelial cells
    Ambrose Y Jong; Fiscal Year: 2010
    ..neoformans internalizes into the HBMEC. The information derived from the studies is expected to be helpful in the development of novel strategies to prevent cryptococcal meningitis and its associated morbidity. ..
  75. Oxidative Stress Markers and HIV Dementia
    Ned Sacktor; Fiscal Year: 2008
    ..We believe that oxidative stress plays a significant role in the development of HIV-D, and strategies to decrease oxidative stress may serve as a useful therapeutic target to treat HIV-D. ..
  76. HIV Prevention Trials Network: Network Laboratory
    Susan Eshleman; Fiscal Year: 2008
    ..Therefore, our agenda is complementary to long-term investments (finding a cure, vaccine, or microbicide). ..
  77. CSF & Lymphocyte Dynamics in HIV Infection
    Richard Price; Fiscal Year: 2009
    ..Beyond its immediate implications for prevention, diagnosis and treatment of Neuro-AIDS, it bears on the understanding other immune, inflammatory and degenerative neurological diseases. ..
  78. Broad Neutralization of HIV-1 from Rhinoviruses Displaying gp41 MPER Sequences
    GAIL ARNOLD; Fiscal Year: 2008
    ....
  79. CORE--DEVELOPMENTAL FACILITY
    Pablo Tebas; Fiscal Year: 2008
    ..We are proposing to fund 5 projects each year in years 6-10 of this CFAR, adding a new grant category devoted exclusively to interdisciplinary and/or translational research projects. ..
  80. ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120
    Abraham Pinter; Fiscal Year: 2000
    ..Modified V1/V2 miniproteins that induce effective neutralizing responses against clinically relevant HIV isolates would provide the basis of a V1/V2-based vaccine against HIV-1. ..
  81. Invasion of C. neoformans into brain endothelial cells
    Ambrose Jong; Fiscal Year: 2009
    ..neoformans internalizes into the HBMEC. The information derived from the studies is expected to be helpful in the development of novel strategies to prevent cryptococcal meningitis and its associated morbidity. ..
  82. Induction of HIV-specific Immune Responses
    Rajesh T Gandhi; Fiscal Year: 2010
    ..By understanding the mechanisms by which immune responses against HIV can be augmented, this may lead to improved ways of treating this disease and may help in developing a vaccine to prevent this infection. ..
  83. The impact of early antiretroviral therapy on HIV persistence and inflammation
    STEVEN GRANT DEEKS; Fiscal Year: 2010
    ..Our work may also provide important insights in the role of chronic inflammation in driving viral persistence, and hence may lead to the development of novel interventions. ..
  84. Structure, Assembly, and Function of Outer Membrane Proteins
    Lukas K Tamm; Fiscal Year: 2010
    ..e. a clinically important pathogen in hospital-induced infections and complications of cystic fibrosis. The research may ultimately contribute to better treatments of these infections. ..
  85. Convergent Chemoenzymatic Synthesis of Glycopeptides and Glycoproteins
    Lai Xi Wang; Fiscal Year: 2008
    ..The knowledge gained from the proposed research will eventually facilitate the development of glycoprotein-based therapeutics. ..
  86. ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120
    Abraham Pinter; Fiscal Year: 2006
    ....
  87. The impact of early antiretroviral therapy on HIV persistence and inflammation
    Steven Deeks; Fiscal Year: 2009
    ..Our work may also provide important insights in the role of chronic inflammation in driving viral persistence, and hence may lead to the development of novel interventions. ..
  88. Invasion of C. neoformans into brain endothelial cells
    Ambrose Jong; Fiscal Year: 2008
    ..The information derived from the studies is expected to be helpful in the development of novel strategies to prevent cryptococcal meningitis and its associated morbidity. ..
  89. HIV Prevention Trials Network: Network Laboratory
    Susan Eshleman; Fiscal Year: 2007
    ..Therefore, our agenda is complementary to long-term investments (finding a cure, vaccine, or microbicide). ..
  90. Treatment&Pathogenesis of Cerebrospinal Fluid HIV Infect
    Richard Price; Fiscal Year: 2002
    ....
  91. ANTIGENIC PROPERTIES OF THE V1/V2 DOMAIN OF HIV-1 GP120
    Abraham Pinter; Fiscal Year: 2003
    ..Modified V1/V2 miniproteins that induce effective neutralizing responses against clinically relevant HIV isolates would provide the basis of a V1/V2-based vaccine against HIV-1. ..
  92. Drug Resistance in Non-Subtype B HIV-1
    Susan Eshleman; Fiscal Year: 2003
    ..abstract_text> ..
  93. Immunologic Control of Drug-resistant HIV-1
    Steven Deeks; Fiscal Year: 2003
    ..Finally, since we will estimate the relative in vivo thresholds for HIV-mediated immunogenicity and pathogenicity, these studies may also have implications for vaccine development. ..
  94. CSF HIV & LYMPHOCYTE DYNAMICS AFTER ANTIVIRAL THERAPY
    Richard Price; Fiscal Year: 2003
    ....
  95. STRUCTURE AND FOLDING OF INTEGRAL MEMBRANE PROTEINS
    LUKAS TAMM; Fiscal Year: 2004
    ..abstract_text> ..